Resumen

ESCALANTE, Cesar  y  GRUPO DE ENDOCRINOLOGIA MERIDA (ENDO-MER) et al. Male hypogonadism management. Rev. Venez. Endocrinol. Metab. [online]. 2015, vol.13, n.2, pp.110-112. ISSN 1690-3110.

Male hypogonadism is characterized by testicular dysfunction secondary to testicular damage and/or hypothalamus-pituitary axis dysfunction resulting in a reduction in testosterone levels. It is classified as hypogonadotropic hypogonadism (Hh) or hypergonadotropic hypogonadism (HH), and these are also divided in acquired and congenital causes. Gonadotropins may be high (HH) or decreased (Hh) and generally occur with decreased testosterone levels. Among the tests supporting the diagnosis and management are included testicular ultrasonography, genetic screening, bone densitometry, testicular biopsy, imaging studies, spermogram, sperm antibodies and hormonal dynamic tests. Finally, testosterone replacement therapy is the main treatment, and the goal is to obtain total testosterone values between 400 and 700 ng/dL. Below, is presented the IAHULA Endocrinology Unit guidelines for male hypogonadism management, based on scientific evidence and clinical experience.

Palabras clave : Male hypogonadism; hypogonadotropic hypogonadism; hypogonadotropic hypogonadism; testosterone.

        · resumen en Español     · texto en Español     · Español ( pdf )